Form 8-K for BioLase Technology, Inc.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

Form 8-K

 


 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

July 19, 2004 (Date of earliest event reported)

 

Commission File Number 000-19627

 


 

BIOLASE TECHNOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

 


 

Delaware   000-19627   87-0442441

(State or Other Jurisdiction of

Incorporation or Organization)

  (Commission file number)  

(I.R.S. Employer

Identification No.)

 

981 Calle Amanecer

San Clemente, California 92673

(Address of Principal Executive Offices, Including Zip Code)

 

(949) 361-1200

(Registrant’s Telephone Number, Including Area Code)

 



Item 5. Other Events and Regulation FD Disclosure.

 

On July 19, 2004, BioLase Technology, Inc. issued a press release announcing its Board of Directors has authorized a 1.25 million share repurchase program. A copy of the press release is attached herewith as Exhibit 99.1.

 

Item 7. Financial Statements and Exhibits.

 

(c) Exhibits.

 

99.1     Press Release, dated July 19, 2004.

 

2


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: July 20, 2004

 

BIOLASE TECHNOLOGY, INC.,

   

(Registrant)

   

By:

 

/s/ EDSON J. ROOD


       

Edson J. Rood

       

Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

3